NKTR earnings: a positive outcome, +7.2%

On March 1, 2022, Nektar Therapeutics reached its earnings. The result was a positive outcome, and the stock moved +7.2% in the window around the event. It had already run -6.3% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.